公开(公告)号：US10752667B2

公开(公告)日：2020-08-25

申请号：US15958608

申请日：2018-04-20

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Carla Lema Tome ,  Sara Ferluga ,  Poonam S. Sonawane

IPC: C07K14/52 ,  C07K14/705 ,  C07K14/54 ,  G01N33/574 ,  A61K38/00

Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Rα2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.

公开(公告)号：US10676529B2

公开(公告)日：2020-06-09

申请号：US15835566

申请日：2017-12-08

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Denise Mazess Herpai

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61K49/00 ,  C12N9/00 ,  A61K47/69 ,  A61K39/00

Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.

公开(公告)号：US20200095302A1

公开(公告)日：2020-03-26

申请号：US16704645

申请日：2019-12-05

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Hetal Pandya ,  Denise Gibo

IPC: C07K14/54 ,  C07K14/195 ,  C07K14/005 ,  C07K19/00 ,  C07K14/21 ,  G01N33/68 ,  G01N33/532 ,  G01N33/50 ,  C07K14/34 ,  A61K47/64

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

公开(公告)号：US20180002394A1

公开(公告)日：2018-01-04

申请号：US15695392

申请日：2017-09-05

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Hetal Pandya ,  Denise Gibo

IPC: C07K14/54 ,  C07K14/005 ,  C07K14/195 ,  C07K14/21 ,  C07K19/00 ,  A61K47/64 ,  G01N33/68 ,  C07K14/34 ,  G01N33/50 ,  G01N33/532 ,  A61K38/00

CPC classification number: C07K14/5437 ,  A61K38/00 ,  A61K47/642 ,  C07K14/005 ,  C07K14/195 ,  C07K14/21 ,  C07K14/34 ,  C07K19/00 ,  C07K2319/01 ,  C07K2319/09 ,  C07K2319/74 ,  G01N33/5008 ,  G01N33/5091 ,  G01N33/532 ,  G01N33/6869 ,  G01N2333/025 ,  G01N2333/195 ,  G01N2333/5437

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

公开(公告)号：US20150203557A1

公开(公告)日：2015-07-23

申请号：US14681355

申请日：2015-04-08

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Hetal Pandya ,  Denise Gibo

IPC: C07K14/54 ,  A61K47/48 ,  G01N33/68 ,  C07K14/195 ,  C07K14/005

CPC classification number: C07K14/5437 ,  A61K38/00 ,  A61K47/642 ,  C07K14/005 ,  C07K14/195 ,  C07K14/21 ,  C07K14/34 ,  C07K19/00 ,  C07K2319/01 ,  C07K2319/09 ,  C07K2319/74 ,  G01N33/5008 ,  G01N33/5091 ,  G01N33/532 ,  G01N33/6869 ,  G01N2333/025 ,  G01N2333/195 ,  G01N2333/5437

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Abstract translation: 一种化合物，其组合包含：细胞表面结合配体或内化因子，例如IL-13Rα2结合配体; 至少一个效应分子（例如，一个，两个，三个或更多个效应分子）; 任选但优选地，共价偶联在所述结合配体和所述至少一个效应分子之间的细胞质定位元件; 以及在所述结合配体和所述至少一个效应分子之间共价偶联的亚细胞区室定位信号元件（优选与所述结合配体和所述亚细胞定位信号元件之间的所述细胞质定位元件）。 还描述了使用这些化合物的方法和含有该化合物的制剂。

公开(公告)号：US09005600B2

公开(公告)日：2015-04-14

申请号：US13718166

申请日：2012-12-18

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Hetal Pandya ,  Denise Gibo

IPC: C07K14/54 ,  A61K38/20 ,  C07K14/21 ,  C07K19/00 ,  C07K14/34 ,  G01N33/50 ,  G01N33/532 ,  G01N33/68 ,  A61K38/00

CPC classification number: C07K14/5437 ,  A61K38/00 ,  A61K47/642 ,  C07K14/005 ,  C07K14/195 ,  C07K14/21 ,  C07K14/34 ,  C07K19/00 ,  C07K2319/01 ,  C07K2319/09 ,  C07K2319/74 ,  G01N33/5008 ,  G01N33/5091 ,  G01N33/532 ,  G01N33/6869 ,  G01N2333/025 ,  G01N2333/195 ,  G01N2333/5437

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Abstract translation: 一种化合物，其组合包含：细胞表面结合配体或内化因子，例如IL-13Rα2结合配体; 至少一个效应分子（例如，一个，两个，三个或更多个效应分子）; 任选但优选地，共价偶联在所述结合配体和所述至少一个效应分子之间的细胞质定位元件; 以及在所述结合配体和所述至少一个效应分子之间共价偶联的亚细胞区室定位信号元件（优选与所述结合配体和所述亚细胞定位信号元件之间的所述细胞质定位元件）。 还描述了使用这些化合物的方法和含有该化合物的制剂。